MF-59

Phase 2Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

MF-59 is one of 47 biologic programs targeting Cytomegalovirus Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cytomegalovirus InfectionActive, not recruiting

InfluenzaActive, not recruiting

Cytomegalovirus InfectionPhase 2

Active, not recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

MF-59

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 8

COMIRNATY

Pfizer

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Influenza

NCT07126652

Clinical

Trials by Indication[1]

Vaccine1 trial

B-19 Parvovirus Vaccine Study

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00379938·43 enrolled

Influenza1 trial

Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial

Not yet recruiting·NNational Taiwan University Hospital·N/A·NCT07126652·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MF-59. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MF-59 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MF-59. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

MF-59

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Vaccine1 trial

Influenza1 trial

Flu Vaccine1 trial

Trial1 trial

Cytomegalovirus Infection1 trial

References

Drug Info

Quick Facts

Related News